ARRAYit Announces New Funding and New Director

                ARRAYit Announces New Funding and New Director

PR Newswire

SUNNYVALE, Calif., Oct. 14, 2013

SUNNYVALE, Calif., Oct. 14, 2013 /PRNewswire/ --ARRAYit Corporation (OTCQB:
ARYC) is pleased to announce a non brokered financing with selected accredited
investors at 30 cents with 50% warrant coverage at $0.45. Closing to be

ARRAYit is also pleased to announce that Sid Taubenfeld R.Ph has joined the
Board Of Directors effective immediately.

Mr. Taubenfeld is a well known Wall Street healthcare analystwho has
workedatmajor Wall Street hedge funds, including Balyasny Asset Management
(BAM), RH Capital and PAW Partners. Additionally, Mr. Taubenfeld served
asDirector of Communications and Strategic Initiatives for Celsion Corp. from
2010-2011 where he facilitated capital raising. Mr. Taubenfeld is a registered
pharmacist and started his career as a clinical pharmacist in the area of
critical medicine and Total Parenteral Nutrition at Bellevue Hospital in NY.

About ARRAYit Corporation

ARRAYit Corporation is a Sunnyvale, California-based company leading and
empowering the genetic, research, pharmaceutical, and diagnostic communities
through the discovery, development, and manufacture of proprietary life
science technologies and consumables for disease prevention, treatment and
cure. The company's innovative products and services help scientists and
clinicians explore the human genome as well as the genomes of plants and
animals. ARRAYit's products are used by nearly every major research center in
the world.

About Liston Street Pulse

Liston Street Pulse is a leading provider of financial research. The company
has significant expertise in U.S. listed small cap and micro-cap stocks.
Subscribe here to read more about ARYC, including CEO interviews.

Safe Harbor Statement

Except for historical information contained herein, statements made in this
release that constitute forward-looking statements are based on currently
available information, involve certain risks and uncertainties and the Company
assumes no responsibility to update any such forward-looking statement. The
following factors, among others, may cause actual results to differ materially
from the results suggested in the forward-looking statements. Risks that may
result from changes in the Company's business operations; our ability to keep
pace with technological advances; significant competition in the biomedical
business; our relationships with key suppliers and customers; quality and
consumer acceptance of newly introduced products; market volatility;
non-availability of product; excess inventory; price and product competition;
new product introductions, the outcome of our legal disputes; the possibility
that the review of our prior filings by the SEC may result in changes to our
financial statements; and the possibility that stockholders or regulatory
authorities may initiate proceedings against ARRAYit and/or our officers and
directors as a result of any restatements. Risk factors associated with our
business, including some of the facts set forth herein, are detailed in the
Company's Form 10-K for the fiscal year ended December 31, 2012 and Form 10-Q
for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal
second quarter ended June 30, 2013.


SOURCE ARRAYit Corporation

Contact: Shas Dey, 201 762 3684,
Press spacebar to pause and continue. Press esc to stop.